Expression of erbB/HER receptors, heregulin and P38 in primary breast cancer using quantitative immunohistochemistry.
- 1 September 2001
- journal article
- research article
- Published by Springer Science and Business Media LLC in Pathology and Oncology Research
- Vol. 7 (3), 171-177
- https://doi.org/10.1007/bf03032345
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53Oncogene, 2001
- Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cellsOncogene, 1999
- Heregulin Regulation of Akt/Protein Kinase B in Breast Cancer CellsBiochemical and Biophysical Research Communications, 1999
- NDF/heregulin-induced cell cycle changes and apoptosis in breast tumour cells: role of PI3 kinase and p38 MAP kinase pathwaysOncogene, 1999
- The oncogenic ErbB-2/ErbB-3 heterodimer is a surrogate receptor of the epidermal growth factor and betacellulinOncogene, 1998
- Epiregulin binds to epidermal growth factor receptor and ErbB-4 and induces tryosine phosphorylation of epidermal growth factor receptor, ErbB-2, ErbB-3 and ErbB-4Oncogene, 1997
- Opposing Effects of ERK and JNK-p38 MAP Kinases on ApoptosisScience, 1995
- The role of erbB2 signal transduction pathways in human breast cancerBreast Cancer Research and Treatment, 1993
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987
- The neu Gene: an erb B-Homologous Gene Distinct from and Unlinked to the Gene Encoding the EGF ReceptorScience, 1985